Palisade Bio Stock (NASDAQ:PALI)

Ownership Financials Chart

Previous Close

$1.68

52W Range

$0.53 - $2.86

50D Avg

$1.99

200D Avg

$1.75

Market Cap

$308.97M

Avg Vol (3M)

$3.69M

Beta

1.54

Div Yield

PALI Company Profile

Palisade Bio, Inc. is a clinical-stage biopharmaceutical firm dedicated to identifying, advancing, and bringing to market orally administered treatments for significant conditions stemming from a compromised gastrointestinal mucosal barrier. The company's primary therapeutic candidate, LB1148, is an oral liquid formulation designed to inhibit digestive enzymes. Its goal is to safeguard gut integrity when the intestine experiences stress due to factors such as diminished blood supply, infections, or surgical procedures. Established in 2005, the company maintains its headquarters in Carlsbad, California.

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

Country

Employees

IPO Date

Mar 30, 2007

Website

PALI Performance

PALI Financial Summary

	Dec 25	Dec 24	Dec 23
Revenue	-	-	$250.00K
Operating Income	$-18.06M	$-14.86M	$-13.07M
Net Income	$-16.78M	$-14.44M	$-12.30M
EBITDA	$-18.06M	$-14.42M	$-12.28M
Basic EPS	$-0.30	$-10.19	$-27.01
Diluted EPS	$-0.30	$-10.19	$-27.01

Fiscal year ends in Dec 25 | Currency in USD

Peer Comparison

Ticker	Company
DARE	Daré Bioscience, Inc.
ASBP	Aspire Biopharma Holdings, Inc.
HOTH	Rocket One Inc.
PCSA	Processa Pharmaceuticals, Inc.
ATHA	Athira Pharma, Inc.
CRIS	Curis, Inc.
BCTX	BriaCell Therapeutics Corp.
LPTX	Leap Therapeutics, Inc.
CTXR	Citius Pharmaceuticals, Inc.